Dec 21, 2004
Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial with HuMax-Inflam/MDX-018

Dec 17, 2004
Roche Selects Two Genmab Antibodies as Clinical Candidates

Dec 16, 2004
Genmab’s HuMax-CD20 to Treat CLL Awarded Fast Track Status from FDA

Dec 13, 2004
US FDA Accepts Genmab’s IND for HuMax-CD20 to Treat Active Rheumatoid Arthritis

Dec 9, 2004
Genmab A/S Financial Calendar for 2005

Dec 4, 2004
Genmab’s HuMax-CD20 Shows Favorable Clinical Responses in NHL

Dec 1, 2004
Genmab Announces Encouraging Efficacy Data from HuMax-EGFr Phase I/II Trial in Head and Neck Cancer

Dec 1, 2004
Grant of Warrants in Genmab A/S

Nov 30, 2004
Genmab to Present at ING 4th Annual European Healthcare Conference

Nov 15, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

Nov 5, 2004
Genmab to Present Data from Phase I/II HuMax-CD20 Study at ASH Conference

Nov 4, 2004
Genmab Appoints Vice President Sales and Marketing

Nov 2, 2004
Genmab Announces Results for the First Nine Months Of 2004

Oct 18, 2004
Additional Data Presented at ACR from AMG 714 Phase II Trial to Treat Rheumatoid Arthritis

Oct 4, 2004
Genmab announces Positive Phase I/II HuMax™-EGFr Safety Data

Sep 23, 2004
Genmab to present at UBS Global Life Sciences Conference

Sep 22, 2004
Dr. Ernst Schweizer extends his Contract as Genmab’s Head of Business Development

Sep 22, 2004
Grant of Warrants in Genmab A/S

Sep 14, 2004
Genmab Achieves Two Milestones in Roche Collaboration

Sep 10, 2004
Phase II AMG 714 Data to be Presented at the American College of Rheumatology Annual Scientific Meeting

Sep 1, 2004
T-Cell Lymphoma Patients Achieve Long Lasting Responses with Genmab’s HuMax-CD4™

Aug 23, 2004
Genmab’s HuMax-CD4 Receives US Orphan Drug Designation

Aug 13, 2004
Genmab Initiates HuMax-CD4 Study in Non-Cutaneous T-Cell Lymphoma

Aug 11, 2004
Genmab to Present HuMax-CD4 Phase II Duration of Response Data

Aug 3, 2004
Grant of Warrants in Genmab A/S

Aug 3, 2004
Genmab Announces 2004 First Half Year Results

Jul 28, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

Jul 1, 2004
Genmab Announces Over-Allotment Option Fully Exercised

Jul 1, 2004
Genmab Announces the Placing of its Private Placement

Jun 30, 2004
Additional Supplement to Preliminary Private Placement Memorandum

Jun 21, 2004
US FDA Accepts Genmab’s IND for HuMax-CD20 to Treat CLL

Jun 21, 2004
Supplement to Preliminary Private Placement Memorandum

Jun 18, 2004
Genmab Announces Private Placement Memorandum in Connection with a Private Placement

Jun 3, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

Jun 1, 2004
Genmab Signs Agreement with DSM Biologics to Produce Clinical and Commercial Supply of HuMax-CD4

May 25, 2004
Genmab's HuMax-CD4 Receives EU Orphan Drug Designation

May 14, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

May 11, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

May 6, 2004
Genmab to Present at ABN Amro 2004 Biotech, Specialty Pharma and Generics Conference

May 6, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

May 4, 2004
Genmab Announces 2004 First Quarter Results

May 4, 2004
Genmab Participates in Merrill Lynch’s Mid Cap Healthcare Conference

Apr 28, 2004
Genmab Announces Positive HuMax-CD4 Phase II Lymphoma Data

Apr 26, 2004
Genmab Licenses Cancer Target from Ganymed

Apr 20, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

Apr 1, 2004
Passing of Genmab A/S' Annual General Meeting -- Subsequent Grant of Warrants

Mar 23, 2004
Amgen Announces Positive HuMax-IL15 Interim Phase II Data

Mar 23, 2004
Genmab’s HuMax-CD4 to Treat Lymphoma Awarded Fast Track Status from FDA

Mar 19, 2004
Roche Selects Two Genmab Antibodies as Clinical Candidates

Mar 16, 2004
Genmab's Annual Report 2003

Mar 10, 2004
Genmab A/S Summons Annual General Meeting

Mar 9, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

Mar 8, 2004
Timing of Publication of Genmab’s Annual Report 2003

Feb 18, 2004
Genmab to Present HuMax-CD4 Data at The Society for Investigative Dermatology Conference

Feb 11, 2004
Capital Increase in Genmab as a Result of Employees' Warrant Exercise

Feb 5, 2004
Genmab Announces Year End 2003 Financial Results

Feb 5, 2004
Preliminary Annual Report 2003

Feb 5, 2004
Capital Increase in Genmab as a Result of Employees’ Warrant Exercise